Cargando…

Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use

BACKGROUND: Desmoid‐type fibromatosis (DTF) has a highly variable clinical course with varying intensity of symptoms. The objectives of this study were to identify subgroups of DTF patients based on physical symptom burden and to compare symptom burden subgroups on health‐related quality of life (HR...

Descripción completa

Detalles Bibliográficos
Autores principales: Schut, Anne‐Rose W., de Bruin, Leanne E., de Rooij, Belle H., Lidington, Emma, Timbergen, Milea J. M., van der Graaf, Winette T. A., van Houdt, Winan J., Bonenkamp, Johannes J., Jones, Robin L., Grünhagen, Dirk. J., Sleijfer, Stefan, Gennatas, Spyridon, Verhoef, Cornelis, Husson, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315709/
https://www.ncbi.nlm.nih.gov/pubmed/37119048
http://dx.doi.org/10.1002/cam4.5985
_version_ 1785067554975252480
author Schut, Anne‐Rose W.
de Bruin, Leanne E.
de Rooij, Belle H.
Lidington, Emma
Timbergen, Milea J. M.
van der Graaf, Winette T. A.
van Houdt, Winan J.
Bonenkamp, Johannes J.
Jones, Robin L.
Grünhagen, Dirk. J.
Sleijfer, Stefan
Gennatas, Spyridon
Verhoef, Cornelis
Husson, Olga
author_facet Schut, Anne‐Rose W.
de Bruin, Leanne E.
de Rooij, Belle H.
Lidington, Emma
Timbergen, Milea J. M.
van der Graaf, Winette T. A.
van Houdt, Winan J.
Bonenkamp, Johannes J.
Jones, Robin L.
Grünhagen, Dirk. J.
Sleijfer, Stefan
Gennatas, Spyridon
Verhoef, Cornelis
Husson, Olga
author_sort Schut, Anne‐Rose W.
collection PubMed
description BACKGROUND: Desmoid‐type fibromatosis (DTF) has a highly variable clinical course with varying intensity of symptoms. The objectives of this study were to identify subgroups of DTF patients based on physical symptom burden and to compare symptom burden subgroups on health‐related quality of life (HRQoL) and healthcare use (univariate and multivariate). METHODS: Desmoid‐type fibromatosis patients from the United Kingdom and the Netherlands received cross‐sectional questionnaires on HRQoL (EORTC QLQ‐C30), DTF‐specific HRQoL (DTF‐QoL) and healthcare utilisation. Latent class cluster analysis was performed to identify subgroups based on patients' symptom burden using EORTC QLQ‐C30 and DTF‐QoL physical symptom items. Multivariate linear and logistic regression analyses were conducted to examine associations of symptom burden with HRQoL and healthcare utilisation, respectively. RESULTS: Among 235 DTF patients, four symptom burden clusters were identified, with low symptom burden (24%), intermediate symptom burden‐low pain (20%), intermediate symptom burden‐high pain (25%) and high symptom burden (31%). DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF‐related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation. CONCLUSIONS: This study identified four distinct subgroups of DTF patients based on their level of symptom burden, with a considerable number of patients being highly symptomatic. Knowledge of the level of symptom burden DTF patients experience can help to identify patients at risk of poorer outcomes and tailor supportive care to the individual needs of DTF patients.
format Online
Article
Text
id pubmed-10315709
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103157092023-07-04 Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use Schut, Anne‐Rose W. de Bruin, Leanne E. de Rooij, Belle H. Lidington, Emma Timbergen, Milea J. M. van der Graaf, Winette T. A. van Houdt, Winan J. Bonenkamp, Johannes J. Jones, Robin L. Grünhagen, Dirk. J. Sleijfer, Stefan Gennatas, Spyridon Verhoef, Cornelis Husson, Olga Cancer Med RESEARCH ARTICLES BACKGROUND: Desmoid‐type fibromatosis (DTF) has a highly variable clinical course with varying intensity of symptoms. The objectives of this study were to identify subgroups of DTF patients based on physical symptom burden and to compare symptom burden subgroups on health‐related quality of life (HRQoL) and healthcare use (univariate and multivariate). METHODS: Desmoid‐type fibromatosis patients from the United Kingdom and the Netherlands received cross‐sectional questionnaires on HRQoL (EORTC QLQ‐C30), DTF‐specific HRQoL (DTF‐QoL) and healthcare utilisation. Latent class cluster analysis was performed to identify subgroups based on patients' symptom burden using EORTC QLQ‐C30 and DTF‐QoL physical symptom items. Multivariate linear and logistic regression analyses were conducted to examine associations of symptom burden with HRQoL and healthcare utilisation, respectively. RESULTS: Among 235 DTF patients, four symptom burden clusters were identified, with low symptom burden (24%), intermediate symptom burden‐low pain (20%), intermediate symptom burden‐high pain (25%) and high symptom burden (31%). DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF‐related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation. CONCLUSIONS: This study identified four distinct subgroups of DTF patients based on their level of symptom burden, with a considerable number of patients being highly symptomatic. Knowledge of the level of symptom burden DTF patients experience can help to identify patients at risk of poorer outcomes and tailor supportive care to the individual needs of DTF patients. John Wiley and Sons Inc. 2023-04-29 /pmc/articles/PMC10315709/ /pubmed/37119048 http://dx.doi.org/10.1002/cam4.5985 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Schut, Anne‐Rose W.
de Bruin, Leanne E.
de Rooij, Belle H.
Lidington, Emma
Timbergen, Milea J. M.
van der Graaf, Winette T. A.
van Houdt, Winan J.
Bonenkamp, Johannes J.
Jones, Robin L.
Grünhagen, Dirk. J.
Sleijfer, Stefan
Gennatas, Spyridon
Verhoef, Cornelis
Husson, Olga
Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
title Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
title_full Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
title_fullStr Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
title_full_unstemmed Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
title_short Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
title_sort physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315709/
https://www.ncbi.nlm.nih.gov/pubmed/37119048
http://dx.doi.org/10.1002/cam4.5985
work_keys_str_mv AT schutannerosew physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT debruinleannee physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT derooijbelleh physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT lidingtonemma physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT timbergenmileajm physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT vandergraafwinetteta physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT vanhoudtwinanj physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT bonenkampjohannesj physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT jonesrobinl physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT grunhagendirkj physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT sleijferstefan physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT gennatasspyridon physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT verhoefcornelis physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse
AT hussonolga physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse